Loading
A phase 2 trial of AdAPT-001 in sarcomas, run by EpicentRx, Inc., active and no longer recruiting.
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors is a phase 2 interventional study registered as NCT04673942 by EpicentRx, Inc., with 140 participants enrolled, started 2021-03-29 and due to reach its primary completion in 2026-12-01. Interventions recorded: AdAPT-001 and Checkpoint Inhibitor, Immune.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares EpicentRx and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares EpicentRx and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/